findmyKOL

Virginia Klimek, MD

Basic profile

Synta Pharmaceuticals

ORCIDNone on fileNPI
RegionNew York, NY · NortheastSpecialtyMedical OncologyFocusOncology
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPaymentsNone reportedNIH fundingNot yet indexedWhy? →

Virginia Klimek is an Oncology physician affiliated with Synta Pharmaceuticals. OpenAlex indexes 165 publications with 11,182 citations (h-index 39); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
165publications

Distinct works indexed by OpenAlex.

11,182citations

Total citations across indexed works.

39h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1275 York Ave
New York, NY 100216007

Telephone

212-639-2000

Registry record last updated 24 Feb 2015.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2020)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    70.7%
    Kinase inhibitor27.2%
    Imatinib Mesylate52%Jakafi48%
    Part D<11 patients
    Antimetabolite25%
    Hydroxyurea100%
    Part D<11 patients

    + 1 more class in this area

  • Anti-infectives

    16.3%
    Fluoroquinolone Antibacterial16.3%
    Levofloxacin100%
    Part D<11 patients
  • Dermatology

    13%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor13%
    Acyclovir100%
    Part D<11 patients
Where care is delivered (Part B)47.6% facility · 52.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”